eCite Digital Repository

Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial

Citation

Fassett, RG and Robertson, IK and Ball, MJ and Geraghty, DP and Sharman, JE and Coombes, JS, Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial, Journal of Atherosclerosis and Thrombosis, 17, (3) pp. 235-241. ISSN 1340-3478 (2010) [Refereed Article]


Preview
PDF
Restricted - Request a copy
154Kb
  

DOI: doi:10.5551/jat.2683

Abstract

Background. Central pulse pressure and measures of arterial stiffness (augmentation index (AIx) and aortic pulse wave velocity (PWV)) predict morbidity and mortality in patients with stage 2-4 chronic kidney disease (CKD). Although statin therapy may be of vascular benefit in patients with CKD, the long-term effect of statins on central pulse pressure and arterial stiffness has not been assessed in this patient population. Methods. We enrolled 37 patients with serum creatinine levels >1.36 mg/dl into a randomized, double blind trial. Patients were allocated to receive 10 mg of atorvastatin per day (19) or placebo (18) for three years. Aortic PWV, AIx, estimated central and brachial blood pressures and were determined every nine months. Results. At baseline, there were no significant differences in aortic PWV, AIx, central or brachial blood pressures between atorvastatin-treated and placebo-treated patients. During the trial, aortic PWV significantly (P=0.021) increased in placebo-treated, but not (P=0.17) in atorvastatin-treated patients (0.51b0.88 vs. 0.18b0.45 m/sec/yr; P=0.20). This represented a 65% (but not statistically significant) slowing of the rate of increase in aortic stiffness. There were no significant changes between groups in the rate of change of AIx (atorvastatin -0.08b5.27 vs. placebo -0.15b5.08 %/yr, P=0.97) or central pulse pressure (atorvastatin -2.52b6.61 vs. placebo -0.45b6.37 mm Hg /yr P=0.53). Conclusion. In patients with CKD arterial stiffness measured by aortic PWV showed a significant increase over time in placebo-treated patients but not in atorvastatin-treated patients. (Trial registration: ACTRN012605000693628)

Item Details

Item Type:Refereed Article
Keywords:Active Australia; Self-Reported Health; Renal Disease, METmins/week
Research Division:Medical and Health Sciences
Research Group:Clinical Sciences
Research Field:Nephrology and Urology
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Urogenital System and Disorders
Author:Robertson, IK (Dr Iain Robertson)
Author:Ball, MJ (Professor Madeleine Ball)
Author:Geraghty, DP (Professor Dominic Geraghty)
Author:Sharman, JE (Professor James Sharman)
ID Code:58287
Year Published:2010
Web of Science® Times Cited:30
Deposited By:Health Sciences A
Deposited On:2009-09-23
Last Modified:2011-04-05
Downloads:2 View Download Statistics

Repository Staff Only: item control page